TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities

Journal of Experimental & Clinical Cancer Research

Gunhild Mechtersheimer³  Andreas von Deimling²  Peter Schirmacher³  Eva Wardelmann⁵  Roland Penzel³  Gerlinde Egerer⁴  Thomas Schmitt⁴  Ingo Alldinger¹  Nina Waldburger³  Burkhard Lehner⁶  Regine Brandt³  Wolfgang Hartmann⁵  Marcus Renner³  Christian Koelsche² 

[1] Department of General, Visceral and Transplantation Surgery, University Hospital, Heidelberg, Germany;German Cancer Consortium (DKTK), CCU Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany;Department of General Pathology, Institute of Pathology, University Hospital, Im Neuenheimer Feld 224, Heidelberg D-69120, Germany;Department of Hematology, Oncology, and Rheumatology, University Hospital, Heidelberg, Germany;Gerhard-Domagk Institute of Pathology, University Hospital, Münster, Germany;Department of Orthopedics and Traumatology, University Hospital, Heidelberg, Germany

关键词: Solitary fibrous tumor;    Myxoid liposarcoma;    Sarcoma;    Soft tissue;    Mutation;    Promoter;    TERT;   

Others  :  804035
DOI  :  10.1186/1756-9966-33-33

 received in 2014-03-04, accepted in 2014-04-08,  发布年份 2014

【 摘 要 】

Background

Recently, recurrent point mutations in the telomerase reverse transcriptase (TERT) promoter region have been found in many human cancers, leading to a new transcription factor binding site, increased induction of TERT and subsequently to telomere maintenance. We determined the prevalence of TERT promoter mutations in soft tissue sarcomas of 341 patients comprising 16 entities and in 16 sarcoma cell lines covering 7 different soft tissue sarcoma types.

Methods

The sarcoma tissue samples were collected from the archives of the Institute of Pathology, University of Heidelberg and were composed of 39 myxoid liposarcomas (MLS), 61 dedifferentiated liposarcomas, 15 pleomorphic liposarcomas, 27 leiomyosarcomas, 25 synovial sarcomas (SS), 35 malignant peripheral nerve sheath tumors (MPNST), 40 undifferentiated pleomorphic sarcomas, 17 myxofibrosarcomas, 9 low grade fibromyxoid sarcomas, 10 cases of dermatofibrosarcoma protuberans, 31 solitary fibrous tumors (SFT), 8 extraskeletal myxoid chondrosarcomas, 9 angiosarcomas, 6 alveolar soft part sarcomas, 5 clear cell sarcomas and 4 epithelioid sarcomas. Sarcoma cell lines were obtained from the raising laboratories. A 193 bp fragment of the TERT promoter region covering the hot-spot mutations C228T and C250T was amplified, and direct sequencing of the PCR products was performed.

Results

TERT promoter mutations were detected in 36/341 sarcomas. They were highly recurrent in MLS (29/39; 74%) and were in the present MLS series not associated with the phenotype (myxoid vs. round cell variant), tumor grade, tumor site and patients’ median age or gender. In the remaining cases, TERT promoter mutations were found only in 7/302 sarcoma samples and confined to SFTs (4/31; 13%), MPNSTs (2/35; 6%), and SSs (1/25; 4%). Within the collection of sarcoma cell lines examined, TERT promoter mutations were detected in two MLS and in one of three MPNST cell lines.

Conclusions

TERT promoter mutations are frequent in MLSs including their round cell variants, representing the most prevalent mutation identified in this sarcoma entity to date, and in a minor fraction of SFTs, MPNSTs and SSs. The majority of sarcomas are devoid of TERT promoter hotspot mutations. These data suggest that telomere maintenance through increased expression of telomerase plays an important role in the pathogenesis especially of MLS.

【 授权许可】

   
2014 Koelsche et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F: WHO Classification of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2013.
• [2]Goldblum JR, Folpe AL, Weiss SW: General Considerations. In In Enzinger and Weiss’s Soft Tissue Tumors. 6th edition. Edited by Enzinger and Weiss’s Soft Tissue Tumors. City: Mosby; 2013:1-10. [Book General Considerations]
• [3]Stojadinovic A, Yeh A, Brennan MF: Completely resected recurrent soft tissue sarcoma: primary anatomic site governs outcomes. J Am Coll Surg 2002, 194:436-447.
• [4]Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M: Advances in sarcoma genomics and new therapeutic targets. Nat Rev Cancer 2011, 11:541-557.
• [5]Renner M, Wolf T, Meyer H, Hartmann W, Penzel R, Ulrich A, Lehner B, Hovestadt V, Czwan E, Egerer G, Schmitt T, Alldinger I, Renker EK, Ehemann V, Eils R, Wardelmann E, Buttner R, Lichter P, Brors B, Schirmacher P, Mechtersheimer G: Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. Genome Biol 2013, 14:r137. BioMed Central Full Text
• [6]van de Rijn M, Fletcher JA: Genetics of soft tissue tumors. Annu Rev Pathol 2006, 1:435-466.
• [7]Xu L, Li S, Stohr BA: The role of telomere biology in cancer. Annu Rev Pathol 2013, 8:49-78.
• [8]Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
• [9]Kyo S, Takakura M, Fujiwara T, Inoue M: Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 2008, 99:1528-1538.
• [10]Heidenreich B, Rachakonda PS, Hemminki K, Kumar R: TERT promoter mutations in cancer development. Curr Opin Genet Dev 2014, 24:30-37.
• [11]Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R: TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
• [12]Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA: Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339:957-959.
• [13]Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K: Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 2013, 126:267-276.
• [14]Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, Susskind D, Grabellus F, Zimmer L, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zeschnigk M: TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer 2013, 109:497-501.
• [15]Griewank KG, Schilling B, Murali R, Bielefeld N, Schwamborn M, Sucker A, Zimmer L, Hillen U, Schaller J, Brenn T, Schadendorf D, Mentzel T: TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. Mod Pathol 2014, 27:502-508.
• [16]Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, Meeker AK, Mertens F, Netto GJ, Rasheed BA, Riggins GJ, Rosenquist TA, Schiffman M, Shih Ie M, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, et al.: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 2013, 110:6021-6026.
• [17]Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Bohmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A: Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 2013, 126:907-915.
• [18]Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA: Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013, 98:E1562-1566.
• [19]Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M: Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013, 20:603-610.
• [20]Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M: Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle 2013, 12:1637-1638.
• [21]Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman Rossi J: High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 2013, 4:2218.
• [22]Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H: TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 2013, 126:931-937.
• [23]Remke M, Ramaswamy V, Peacock J, Shih DJ, Koelsche C, Northcott PA, Hill N, Cavalli FM, Kool M, Wang X, Mack SC, Barszczyk M, Morrissy AS, Wu X, Agnihotri S, Luu B, Jones DT, Garzia L, Dubuc AM, Zhukova N, Vanner R, Kros JM, French PJ, Van Meir EG, Vibhakar R, Zitterbart K, Chan JA, Bognar L, Klekner A, Lach B, et al.: TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol 2013, 126:917-929.
• [24]Scott GA, Laughlin TS, Rothberg PG: Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol 2014, 27:516-523.
• [25]Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L, Melo M, da Rocha AG, Preto A, Castro P, Castro L, Pardal F, Lopes JM, Santos LL, Reis RM, Cameselle-Teijeiro J, Sobrinho-Simoes M, Lima J, Maximo V, Soares P: Frequency of TERT promoter mutations in human cancers. Nat Commun 2013, 4:2185.
• [26]Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M: High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 2014, 24:184-189.
• [27]Schneider-Stock R, Jaeger V, Rys J, Epplen JT, Roessner A: High telomerase activity and high HTRT mRNA expression differentiate pure myxoid and myxoid/round-cell liposarcomas. Int J Cancer 2000, 89:63-68.
• [28]Costa A, Daidone MG, Daprai L, Villa R, Cantu S, Pilotti S, Mariani L, Gronchi A, Henson JD, Reddel RR, Zaffaroni N: Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression. Cancer Res 2006, 66:8918-8924.
• [29]Matsuo T, Shimose S, Kubo T, Fujimori J, Yasunaga Y, Sugita T, Ochi M: Correlation between p38 mitogen-activated protein kinase and human telomerase reverse transcriptase in sarcomas. J Exp Clin Cancer Res 2012, 31:5. BioMed Central Full Text
• [30]Schneider-Stock R, Boltze C, Jager V, Epplen J, Landt O, Peters B, Rys J, Roessner A: Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J Pathol 2003, 199:517-525.
• [31]Yan P, Benhattar J, Coindre JM, Guillou L: Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlate with telomere length in soft tissue sarcomas. Int J Cancer 2002, 98:851-856.
• [32]Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998, 58:4168-4172.
• [33]Zhu S, Rousseau P, Lauzon C, Gandin V, Topisirovic I, Autexier C: Inactive C-terminal telomerase reverse transcriptase insertion splicing variants are dominant-negative inhibitors of telomerase. Biochimie 2014. doi: 10.1016/j.biochi.2013.12.023
• [34]Cifuentes-Rojas C, Shippen DE: Telomerase regulation. Mutat Res 2012, 730:20-27.
• [35]Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, Bettegowda C, Rodriguez FJ, Eberhart CG, Hebbar S, Offerhaus GJ, McLendon R, Rasheed BA, He Y, Yan H, Bigner DD, Oba-Shinjo SM, Marie SK, Riggins GJ, Kinzler KW, Vogelstein B, Hruban RH, Maitra A, Papadopoulos N, Meeker AK: Altered telomeres in tumors with ATRX and DAXX mutations. Science 2011, 333:425.
• [36]Henson JD, Reddel RR: Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers. FEBS Lett 2010, 584:3800-3811.
• [37]Cairney CJ, Hoare SF, Daidone MG, Zaffaroni N, Keith WN: High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma. Br J Cancer 2008, 98:1467-1474.
• [38]Venturini L, Motta R, Gronchi A, Daidone M, Zaffaroni N: Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. BMC Cancer 2010, 10:254. BioMed Central Full Text
• [39]Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR: A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005, 11:217-225.
• [40]Johnson JE, Gettings EJ, Schwalm J, Pei J, Testa JR, Litwin S, von Mehren M, Broccoli D: Whole-genome profiling in liposarcomas reveals genetic alterations common to specific telomere maintenance mechanisms. Cancer Res 2007, 67:9221-9228.
• [41]Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK: Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 2004, 164:1523-1529.
• [42]Dei Tos AP: Liposarcomas: diagnostic pitfalls and new insights. Histopathology 2014, 64:38-52.
• [43]Fritz B, Schubert F, Wrobel G, Schwaenen C, Wessendorf S, Nessling M, Korz C, Rieker RJ, Montgomery K, Kucherlapati R, Mechtersheimer G, Eils R, Joos S, Lichter P: Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res 2002, 62:2993-2998.
• [44]Pilotti S, Della Torre G, Lavarino C, Sozzi G, Minoletti F, Vergani B, Azzarelli A, Rilke F, Pierotti MA: Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J Pathol 1998, 185:188-190.
• [45]Rieker RJ, Joos S, Bartsch C, Willeke F, Schwarzbach M, Otano-Joos M, Ohl S, Hogel J, Lehnert T, Lichter P, Otto HF, Mechtersheimer G: Distinct chromosomal imbalances in pleomorphic and in high-grade dedifferentiated liposarcomas. Int J Cancer 2002, 99:68-73.
• [46]Dalal KM, Kattan MW, Antonescu CR, Brennan MF, Singer S: Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 2006, 244:381-391.
• [47]Hakin-Smith V, Jellinek DA, Levy D, Carroll T, Teo M, Timperley WR, McKay MJ, Reddel RR, Royds JA: Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003, 361:836-838.
• [48]Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W: ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013, 126:443-451.
• [49]Schweizer L, Koelsche C, Sahm F, Piro RM, Capper D, Reuss DE, Pusch S, Habel A, Meyer J, Gock T, Jones DT, Mawrin C, Schittenhelm J, Becker A, Heim S, Simon M, Herold-Mende C, Mechtersheimer G, Paulus W, Konig R, Wiestler OD, Pfister SM, von Deimling A: Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol 2013, 125:651-658.
• [50]Mantripragada KK, Caley M, Stephens P, Jones CJ, Kluwe L, Guha A, Mautner V, Upadhyaya M: Telomerase activity is a biomarker for high grade malignant peripheral nerve sheath tumors in neurofibromatosis type 1 individuals. Genes Chromosomes Cancer 2008, 47:238-246.
• [51]Rodriguez FJ, Folpe AL, Giannini C, Perry A: Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems. Acta Neuropathol 2012, 123:295-319.
• [52]Venturini L, Daidone MG, Motta R, Cimino-Reale G, Hoare SF, Gronchi A, Folini M, Keith WN, Zaffaroni N: Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. Neuro Oncol 2012, 14:736-744.
• [53]Sangiorgi L, Gobbi GA, Lucarelli E, Sartorio SM, Mordenti M, Ghedini I, Maini V, Scrimieri F, Reggiani M, Bertoja AZ, Benassi MS, Picci P: Presence of telomerase activity in different musculoskeletal tumor histotypes and correlation with aggressiveness. Int J Cancer 2001, 95:156-161.